Identification of the best available donor based on KIR genotypes, using the weighted tiered algorithm in all evaluated patients. Recipients with >1 donor are divided based on KIR ligand: HLA-C1⁺/HLA-Bw4⁺ recipients had donors prioritized for KIR3DL1 inhibition, followed by KIR2DS1, and then cenBB. HLA-C1⁺/HLA-Bw4⁻ recipients had donors prioritized for KIR2DS1, followed by cenBB.